Reprogrammed viruses as cancer therapeutics: Targeted, armed and shielded

Roberto Cattaneo; Tanner Miest; Elena V. Shashkova; Michael A. Barry

doi:10.1038/nrmicro1927

Reprogrammed viruses as cancer therapeutics: Targeted, armed and shielded

Roberto Cattaneo, Tanner Miest, Elena V. Shashkova, Michael A. Barry

Research output: Contribution to journal › Review article › peer-review

277 Scopus citations

Abstract

Virotherapy is currently undergoing a renaissance, based on our improved understanding of virus biology and genetics and our better knowledge of many different types of cancer. Viruses can be reprogrammed into oncolytic vectors by combining three types of modification: targeting, arming and shielding. Targeting introduces multiple layers of cancer specificity and improves safety and efficacy; arming occurs through the expression of prodrug convertases and cytokines; and coating with polymers and the sequential usage of different envelopes or capsids provides shielding from the host immune response. Virus-based therapeutics are beginning to find their place in cancer clinical practice, in combination with chemotherapy and radiation.

Original language	English (US)
Pages (from-to)	529-540
Number of pages	12
Journal	Nature Reviews Microbiology
Volume	6
Issue number	7
DOIs	https://doi.org/10.1038/nrmicro1927
State	Published - Jul 2008

ASJC Scopus subject areas

Microbiology
General Immunology and Microbiology
Infectious Diseases

Access to Document

10.1038/nrmicro1927

Cite this

@article{4f828e2d96e24fcfbf845c857f5361d7,

title = "Reprogrammed viruses as cancer therapeutics: Targeted, armed and shielded",

abstract = "Virotherapy is currently undergoing a renaissance, based on our improved understanding of virus biology and genetics and our better knowledge of many different types of cancer. Viruses can be reprogrammed into oncolytic vectors by combining three types of modification: targeting, arming and shielding. Targeting introduces multiple layers of cancer specificity and improves safety and efficacy; arming occurs through the expression of prodrug convertases and cytokines; and coating with polymers and the sequential usage of different envelopes or capsids provides shielding from the host immune response. Virus-based therapeutics are beginning to find their place in cancer clinical practice, in combination with chemotherapy and radiation.",

author = "Roberto Cattaneo and Tanner Miest and Shashkova, {Elena V.} and Barry, {Michael A.}",

note = "Funding Information: R.C. has been supported by the National Institutes of Health (grant CA90636) and the Alliance of Cancer Gene Therapy. M.A.B. has been supported by the Department of Defense (grant W81XWH-05-1-0269) and the Susan G. Komen Foundation (grant BCTR0504036).",

year = "2008",

month = jul,

doi = "10.1038/nrmicro1927",

language = "English (US)",

volume = "6",

pages = "529--540",

journal = "Nature Reviews Microbiology",

issn = "1740-1526",

publisher = "Nature Publishing Group",

number = "7",

}

TY - JOUR

T1 - Reprogrammed viruses as cancer therapeutics

T2 - Targeted, armed and shielded

AU - Cattaneo, Roberto

AU - Miest, Tanner

AU - Shashkova, Elena V.

AU - Barry, Michael A.

N1 - Funding Information: R.C. has been supported by the National Institutes of Health (grant CA90636) and the Alliance of Cancer Gene Therapy. M.A.B. has been supported by the Department of Defense (grant W81XWH-05-1-0269) and the Susan G. Komen Foundation (grant BCTR0504036).

PY - 2008/7

Y1 - 2008/7

N2 - Virotherapy is currently undergoing a renaissance, based on our improved understanding of virus biology and genetics and our better knowledge of many different types of cancer. Viruses can be reprogrammed into oncolytic vectors by combining three types of modification: targeting, arming and shielding. Targeting introduces multiple layers of cancer specificity and improves safety and efficacy; arming occurs through the expression of prodrug convertases and cytokines; and coating with polymers and the sequential usage of different envelopes or capsids provides shielding from the host immune response. Virus-based therapeutics are beginning to find their place in cancer clinical practice, in combination with chemotherapy and radiation.

AB - Virotherapy is currently undergoing a renaissance, based on our improved understanding of virus biology and genetics and our better knowledge of many different types of cancer. Viruses can be reprogrammed into oncolytic vectors by combining three types of modification: targeting, arming and shielding. Targeting introduces multiple layers of cancer specificity and improves safety and efficacy; arming occurs through the expression of prodrug convertases and cytokines; and coating with polymers and the sequential usage of different envelopes or capsids provides shielding from the host immune response. Virus-based therapeutics are beginning to find their place in cancer clinical practice, in combination with chemotherapy and radiation.

UR - http://www.scopus.com/inward/record.url?scp=45449114994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45449114994&partnerID=8YFLogxK

U2 - 10.1038/nrmicro1927

DO - 10.1038/nrmicro1927

M3 - Review article

C2 - 18552863

AN - SCOPUS:45449114994

SN - 1740-1526

VL - 6

SP - 529

EP - 540

JO - Nature Reviews Microbiology

JF - Nature Reviews Microbiology

IS - 7

ER -

Reprogrammed viruses as cancer therapeutics: Targeted, armed and shielded

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this